An Ion Channel Reignites Immune Attack on Cancer

Cancer metastasis remains the leading cause of cancer-related mortality worldwide, and metastasizing cancer cells often exhibit physical properties markedly different from those of healthy cells. Recent studies have revealed that metastatic cancer cells are generally softer and more deformable than normal cells. This "softness" is no coincidence—it allows cancer cells to squeeze through blood vessel walls and establish secondary tumors in distant tissues. However, this biomechanical flexibility comes with a crucial side effect: it makes it difficult for natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) within the immune system to effectively engage and attack them. According to World Health Organization estimates, breast cancer ranks as the most commonly diagnosed malignancy among women globally, with approximately 2.3 million new cases in 2022, while the 5-year survival rate for metastatic breast cancer patients remains below 30%.

Recently, a study published in the journal Developmental Cell, titled "Ionic regulation of cancer cell stiffness and metastatic colonization via the MRTFA-KCNMB1 axis," provided a promising breakthrough to resolve this dilemma. Conducted by researchers at the University of Illinois Chicago and collaborating institutions, the core discovery centers around an ion channel protein designated KCNMB1—an auxiliary subunit of large-conductance calcium-activated potassium (BK) channels responsible for regulating transmembrane potassium flux.

Researchers previously knew that a protein called myocardin-related transcription factor A (MRTFA) increases cellular stiffness. However, as a transcription factor positioned upstream in signaling pathways, directly targeting MRTFA could trigger widespread, uncontrolled downstream off-target effects, making it a challenging therapeutic target. The researchers instead shifted their approach to search for downstream genes co-activated with MRTFA. By comparing gene expression profiles alongside a series of validation experiments, they zeroed in on a previously overlooked candidate: KCNMB1.

Surprisingly, KCNMB1 exerted diametrically opposite effects depending on the cell type. In primary pericytes, knocking down KCNMB1 increased cell stiffness, consistent with potassium efflux promoting relaxation during excitation-contraction coupling. In cancer cells, however, KCNMB1 knockdown actually made the cells softer. This contrast indicates that potassium regulation mechanisms in cancer cells have diverged from normal physiological pathways, with KCNMB1 serving as a key control node along this altered trajectory.

When researchers boosted KCNMB1 activity, the stiffness of cancer cells increased significantly. This alteration in physical state yielded direct biological consequences: hardened cancer cells became far more susceptible to NK cell-mediated cytotoxic killing, eliminating the biomechanical cushion that previously prevented immune cells from mounting an effective attack. Animal experiments further validated this concept—in mouse models of metastatic breast cancer, pharmacological activation of BK channels using the agonist BMS-204352 significantly reduced distant metastatic burden in the lungs while restoring the lytic capability of cytotoxic T lymphocytes against cancer cells. Notably, this therapeutic effect depended on the presence of functional T cells, demonstrating that the strategy works at least in part by improving immune recognition and clearance of metastatic cells.

Figure 1. BK channel agonist treatment hinders metastatic colonization. (Gajda A M, et al., 2026)

The clinical relevance of these findings was corroborated by breast cancer patient data. Analyses revealed that patients with low KCNMB1 expression experienced significantly shorter survival times, suggesting that this molecular biomarker is closely tied to disease progression and immune evasion. Furthermore, the study uncovered that the tumor microenvironment itself is characteristically potassium-rich. This high-potassium environment further softens and suppresses cancer cells while simultaneously blunting immune cell activity. Activating BK channels reverses this disadvantageous state, directly linking physical shifts in cell rigidity to the efficiency of immune attack and defense.

This study opens a novel "biomechanical frontier." While traditional anti-cancer strategies focus primarily on molecular signaling pathways or immune checkpoints, this research approaches the problem from a cell mechanics perspective, demonstrating that ion channels can modulate cell stiffness to influence immune-killing efficacy. Crucially, ion channels represent a mature class of clinical drug targets, with several ion channel-targeting therapies already approved for cardiovascular diseases and stroke. This establishes a solid pharmacological foundation and a clear translational path for advancing BK channel agonists into oncology.

While still in the preclinical stage requiring further validation before reaching patients, this work clearly points in a promising direction: "toughening up" cancer cells is far from science fiction, but rather a realistic strategy to mobilize the immune system against metastatic tumors. When cancer cells use extreme softness to bounce off immune attacks like jelly, a precise ion channel modulator might be just what is needed to turn the tide.